PROM1 and neoplasm: In pancreatic cancer, CSCs were first characterized as CD44+CD24+ESA+ cells with the ability to develop tumors at a higher frequency than the cells from tumor bulk.[13] CD133 has also been used to identify CSCs from both human primary pancreatic tumor tissues and cell lines [18].